(MENAFN- GlobeNewsWire - Nasdaq) Market opportunities in the IBD treatment sector include the rising demand for targeted therapies and biologics due to a deeper understanding of the disease, alongside the expansion of biosimilar access. Growth is fueled by increasing diagnosis rates and advanced therapies. Asia-Pacific offers rapid growth potential amid rising healthcare investments.

Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033" report has been added to ResearchAndMarkets's offering.
The global inflammatory bowel disease (IBD) treatment market is projected to grow at a CAGR of 5.5% from 2025 to 2033, driven by the rising prevalence of Crohn's disease and ulcerative colitis, increasing diagnosis rates, and continuous innovation in biologics and advanced therapies. The adoption of advanced monoclonal antibodies, biosimilars, and targeted therapies is reshaping patient management and improving outcomes.

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The 2024 market was dominated by leading pharmaceutical companies focusing on biologics, biosimilars, and next-generation therapies. AbbVie remains a key player with its blockbuster drug Humira and next-generation Rinvoq and Skyrizi for IBD treatment. Johnson & Johnson, Takeda Pharmaceuticals, Pfizer, and Amgen have strong portfolios in biologics and immunotherapies.

UCB, Biogen, and Eli Lilly are expanding through targeted therapies and pipeline candidates. Celltrion, Alvotech, and Organon are prominent in the biosimilars segment, offering cost-effective alternatives. Boehringer Ingelheim, Ferring, and Dr Falk Pharma contribute specialized gastrointestinal treatment portfolios. Competitive strategies are driven by biologic lifecycle management, biosimilar entry, patient-focused programs, and expansion into emerging markets.

In 2024, North America led the IBD treatment market, supported by high disease prevalence, strong healthcare infrastructure, and widespread biologic adoption. Europe followed, driven by reimbursement support for biologics and the rising uptake of biosimilars in countries such as Germany, the UK, and France.

Asia-Pacific is the fastest-growing region, as increasing awareness, expanding diagnostic facilities, and the launch of biosimilars fuel market penetration in China, Japan, and India. Latin America and Middle East & Africa (MEA) remain emerging markets, where limited access to advanced therapies is gradually improving due to rising healthcare investment and patient support programs.
Rising Demand for Targeted Therapies and Biologics
Growing understanding of IBD pathophysiology is driving demand for targeted treatment options, especially biologics and biosimilars. Physicians are increasingly prescribing advanced therapies for moderate-to-severe cases, while patients seek better quality of life with treatments that reduce hospitalizations and surgery rates. The entry of cost-effective biosimilars is also accelerating access to biologic therapies globally. Combination therapy and personalized treatment strategies, often incorporating biologics with immunomodulators, are further expanding treatment approaches.
Challenges: High Costs and Variable Access
Despite the expanding market, challenges persist. High treatment costs, particularly for biologics and novel agents, limit accessibility in price-sensitive markets. Uneven reimbursement policies and healthcare infrastructure disparities across regions also hinder adoption. In addition, safety concerns such as infection risk, loss of response to biologics, and the need for lifelong treatment complicate long-term management. However, broader biosimilar availability, ongoing R&D in oral small molecules, and increased healthcare funding are expected to reduce these barriers over time.
Market Segmentation by Treatment Type
By treatment type, the market is divided into Crohn's disease and ulcerative colitis therapies. Crohn's disease represents a significant portion of the market due to the complexity of treatment and high relapse rates, requiring ongoing innovation in biologics and immunotherapies. Ulcerative colitis remains a substantial segment, with recent approvals of targeted therapies improving long-term disease management and remission rates.
Market Segmentation by Drug Class
By drug class, the market is segmented into first-line treatment, second-line treatment, and combination therapy. First-line treatments include corticosteroids, aminosalicylates, and immunosuppressants, primarily used for mild-to-moderate cases. Second-line treatment, dominated by biologics such as TNF inhibitors, JAK inhibitors, and integrin antagonists, accounts for the largest revenue share due to adoption in moderate-to-severe IBD cases. Combination therapy is emerging as a critical strategy, offering enhanced efficacy for patients unresponsive to single-agent treatments.

Key questions answered in this report:

• What are the key micro and macro environmental factors that are impacting the growth of Inflammatory Bowel Disease Treatment market?
• What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2033.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Inflammatory Bowel Disease Treatment market?
• Which is the largest regional market for Inflammatory Bowel Disease Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia-Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Inflammatory Bowel Disease Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Inflammatory Bowel Disease Treatment market worldwide?

Inflammatory Bowel Disease Treatment Market: Macro Analysis & Market Dynamics

• Global Inflammatory Bowel Disease Treatment Market Value, 2023-2033, (US$ Million)
• Market Dynamics
• Market Drivers
• Market Restraints
• Key Challenges
• Key Opportunities
• Impact Analysis of Drivers and Restraints
• Porter's Five Force Model
• PESTEL Analysis

Companies Featured

• AbbVie
• Alvotech
• Amgen
• Biogen
• Boehringer Ingelheim
• Celltrion
• Dr Falk Pharma
• Eli Lilly
• Ferring
• Johnson & Johnson
• ORGANON
• Pfizer
• Takeda Pharmaceuticals

Market Segmentation

Treatment Type

• Crohn's disease
• Ulcerative colitis

Drug Class

First-line treatment

• Aminosalicylates
• Corticosteroids

Second-line treatment

• IL inhibitors
• TNF inhibitors
• JAK inhibitors
• Anti-integrin
• S1P receptor modulator

Combination therapy

• TNF inhibitors + thiopurines
• Other combination therapies

Route of Administration

• Injectable
• Oral
• Rectal

Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

Regional Segmentation (2023-2033; US$ Million)

North America

• U.S.
• Canada
• Rest of North America

UK and European Union

• UK
• Germany
• Spain
• Italy
• France
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East and Africa

• GCC
• Africa
• Rest of Middle East and Africa

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN20112025004107003653ID1110372838